Parexel appoints Charlotte Moser as its Chief Medical Officer

New Delhi: Parexel, one of the world’s leading clinical research organizations (CROs) has appointed Dr Charlotte Moser as Chief Medical Officer.

As Chief Medical Officer for Parexel, Dr Moser will provide medical and scientific leadership globally, building on the company’s regulatory and therapeutic expertise with a significant focus on innovative drug development strategies and clinical trial design. With more than 25 years of experience in the life sciences industry, she brings a unique combination of strategic clinical development leadership as well asexperience as a principal investigator.

Dr Moser has served as head of clinical development at biotechnology and life sciences companies, bringing her clinical expertise to the early development of targeted oncology diagnostics and therapeutics and working closely with globalregulators to support the approval of new therapies. Her proven ability to drive drug and medical device strategy and development make her well-suited to lead Parexel’s diverse portfolio of clinical research services across a broad range of therapeutic areas.

“I’m delighted to join an organization at the forefront of patient-focused drug development and healthcare innovation, with differentiated expertise in meeting the needs of life sciences customers worldwide,” said Dr. Moser. “I look forward to working with our global expertteam on programs in different countries and across specific patient and local healthcare needs — all with the goal of supporting our customers in the development of ground-breaking therapies for patients.”

“We’re thrilled to welcome Dr. Moser to Parexel,” said Peyton Howell, Chief Executive Officer. “As a clinician, she embodies Parexel’sdedication to keeping patients at the heart of everything we do. Additionally, her unique perspectives as a biotech leader and practicing oncologist — along with her proven track record in delivery of clinical trials around the globe — will be invaluable to our team andcustomers as we continue to accelerate the delivery of life-changing therapies to patients.” 

Prior to joining Parexel, Dr. Moser was Senior Vice President of Clinical Development for Celcuity Inc., a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. She earned an MD from Vrije University Amsterdam and completed oncology training and earned a PhD in Biostatistics at the University of Leiden in The Netherlands. Dr. Moseralso earned an MBA from the MIT Sloan School of Management and a certificate in drug development (Oncology and Cancer Biology) from Harvard Medical School.